#Neuroscience
Brain-targeted peptide work: nootropics, neuroprotection, stroke recovery.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
Why Semax Comes as a Nasal Spray
Semax is a Russian-registered nasal-spray peptide with no FDA or EU approval. Here is what the intranasal evidence actually supports.
PT-141 vs semaglutide: two brain targets
Both peptides act on brain receptors, and that is where the similarity stops. One is licensed for low sexual desire, the other for weight and heart risk.
What the EVOKE Alzheimer's trials found
In the EVOKE and EVOKE+ trials, oral semaglutide reduced Alzheimer's-linked biomarkers but did not slow cognitive or functional decline.
Stacking GLP-1 Drugs With Mood Peptides
Tirzepatide and retatrutide users sometimes add peptides like Semax for energy or mood. Here is what the trial evidence actually supports.
GIP receptors and brain dopamine in mice
A 2026 mouse study found GIP receptors in the lateral septum, where GIP and GLP-1 agonists cut electrically evoked dopamine release.
What is food noise? Five theories
A 2026 Appetite review says food noise still has no settled definition. Here are the five theories behind it, and what the GLP-1 survey data shows.
Oral Semaglutide and Cognitive Decline Risk
A small elderly-cohort study links oral semaglutide to less cognitive impairment than DPP-4 inhibitors, but a large Alzheimer's trial found no benefit.
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
Semaglutide and Alzheimer's after EVOKE
Semaglutide failed both EVOKE Alzheimer's trials. A new paper argues research should shift from one hypothesis to a stratified program.
Orzeyful isn't Ozempic for the brain
The FDA approved oveporexton for narcolepsy in August 2026. It targets the neuropeptide orexin, but the drug itself is not a peptide like semaglutide.
Semaglutide, obesity, and chronic migraine
A 2026 letter in Headache argues semaglutide may break a loop in which obesity worsens migraine and fasting-driven avoidance triggers more attacks.